Development of a decision-making tool to predict risk of prostate cancer: The Cancer of the Prostate Risk Index (CAPRI) test

Urology

Volumn 50, Issue 5, 1997, Pages 665-672

  Optenberg, Scott A ^a   Clark, Joseph Y ^b   Brawer, Michael K ^b   Thompson, Ian M ^b   Stein, Catherine R ^b   Friedrichs, Paul ^b  

^a Ctr for Hlthcare Educ and Studies   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; POPULATION RISK; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC;

AGE FACTORS; AGED; BIOPSY; CONTINENTAL POPULATION GROUPS; HUMANS; MALE; MIDDLE AGED; PALPATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0030665917     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00451-2     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Kramer BS, Brown ML, Prorok PC, Potosky AL, and Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119: 914-923, 1993.
3. US Preventive Services Task Force: Guide to Clinical Preventive Services, 2nd ed. Baltimore, Williams & Wilkins, 1995, pp 119-134.
4. Phillips TH, and Thompson IM: Digital rectal examination and carcinoma of the prostate. Urol Clin North Am 18: 459-465, 1991.
5. Smith DS, and Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45: 70-74, 1995.
6. Blair A, and Fraumeni JF Jr: Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 61: 1379-1384, 1978.
7. Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, and Kramer B: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 274: 1599-1605, 1995.
8. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, and Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76: 45-48, 1986.
9. Silverberg E: Statistical and epidemiologic data on urologic cancer. Cancer 60(suppl): 692-717, 1987.
10. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al: Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652-661, 1995.
11. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
12. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, and Stone NN: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48: 234-239, 1996.
13. Oesterling JE, Jacobsen SJ, and Cooner WH: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153: 1160-1163, 1995.
14. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, and Babaian R: Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 74: 3146-3158, 1994.
15. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
16. Hosmer DW, and Lemeshow S: Applied Logistic Regression. New York, Wiley, & Sons, 1989.
17. Smith DWE: Cancer mortality at very old ages. Cancer 77: 1367-1372, 1996.
18. Bretton PR, Evans WP, Borden JD, and Castellanos RD: The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer 74: 2991-2995, 1994.
19. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, and McLeod DG: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274: 1277-1281, 1995.
20. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, and Awan AM: Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev 1: 541-545, 1992.
21. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, and Moul JW: Age-specific reference ranges for serum prostate-specific antigen in black men. New Engl J Med 335: 304-310, 1996.
22. Snow PB, Smith DS, and Catalona WJ: Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 152 (5 Pt 2): 1923-1926, 1994.